Abstract
MAJOR FINDING: ROS1 chromosomal rearrangements define a molecular subtype of NSCLC.
Impact:
ROS1 rearrangements tend to occur in younger, non-smoking NSCLC patients.
Clinical relevance:
ROS1-positive NSCLC patients may benefit from crizotinib therapy.
MeSH terms
-
Carcinoma, Non-Small-Cell Lung / genetics*
-
Gene Rearrangement
-
Humans
-
Lung Neoplasms / genetics*
-
Protein-Tyrosine Kinases / genetics*
-
Proto-Oncogene Proteins / genetics*
Substances
-
Proto-Oncogene Proteins
-
Protein-Tyrosine Kinases
-
ROS1 protein, human